Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

Quick Access

Favorites
Most Used

All Specialties

OpiCalc Logo
Clinical CalculatorsDrugsGuidelines
SpecsDrugsGuides
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub
Intravenous Electrolyte Solution/Discontinued

ACETATED RINGER'S IN PLASTIC CONTAINER

ACETATED RINGER'S IN PLASTIC CONTAINER

Clinical safety rating

caution

Comprehensive clinical and safety monograph for ACETATED RINGER'S IN PLASTIC CONTAINER (ACETATED RINGER'S IN PLASTIC CONTAINER).


Mechanism of Action

Acetated Ringer's solution provides isotonic crystalloid fluid and electrolytes, with acetate as a bicarbonate precursor metabolized in the liver and peripheral tissues, buffering metabolic acidosis. It restores intravascular volume and corrects electrolyte imbalances.

What the body does with it

MetabolismAcetate is metabolized via acetyl-CoA in the tricarboxylic acid cycle, yielding bicarbonate; primary sites include liver and skeletal muscle.
ExcretionAcetated Ringer's solution components are excreted primarily renally: water (100% via kidneys), sodium (90-95% renal, 5-10% sweat/feces), chloride (90-95% renal), acetate (metabolized to bicarbonate, then CO2 excreted via lungs; <5% renal), potassium (80-90% renal, 10-20% feces), calcium (98% renal reabsorption, <2% fecal), magnesium (70% renal, 30% fecal).
Half-lifeNot applicable as a fixed half-life; components distribute and equilibrate rapidly. For administered volume, intravascular half-life is 20-30 minutes due to redistribution to interstitial space. Electrolyte half-lives: sodium ~8-12 hours, chloride ~8-12 hours, potassium ~12-24 hours, calcium ~24-48 hours, magnesium ~24-48 hours.
Protein bindingCalcium: ~40% bound to albumin; magnesium: ~30% bound to albumin; other components (sodium, potassium, chloride, acetate) have negligible protein binding (<5%).
Volume of DistributionNot a single value for all components. Water distributes into total body water (0.6 L/kg), sodium and chloride primarily into extracellular fluid (0.2 L/kg), potassium into intracellular fluid (0.4 L/kg), calcium and magnesium into bone and cells (Vd ~0.5-0.8 L/kg).
BioavailabilityIntravenous: 100% (only route administered). Oral: not applicable; not administered orally.
Onset of ActionIntravenous: immediate (within seconds) for volume expansion; electrolyte effects begin within minutes.
Duration of ActionIntravenous: volume effects last 30-60 minutes for 1 L infusion under normal conditions; longer in hypovolemia. Electrolyte effects persist for hours to days depending on excretion/regulation, e.g., potassium repletion duration ~2-4 hours after infusion.
Molecular WeightVaries by component: water 18.02, sodium 22.99, chloride 35.45, acetate 59.04; overall solution not a single compound.

Classification & Brands

Dosing & administration

Intravenous infusion; dosing based on patient's fluid and electrolyte needs. Typical adult dose: 500-1000 mL per hour as needed for volume replacement; adjust rate based on clinical response and serum electrolyte monitoring.

Dosage formINJECTABLE
Renal impairmentNo specific GFR-based dose adjustment required; however, use with caution in renal impairment due to risk of fluid overload and electrolyte imbalances. Monitor serum potassium and renal function.
Liver impairmentNo specific Child-Pugh dose adjustment; use with caution in severe hepatic impairment due to potential altered lactate metabolism. Monitor electrolytes and acid-base status.
Pediatric useWeight-based dosing: 20-30 mL/kg as a bolus over 30-60 minutes for volume expansion; maintenance: adjust based on fluid deficit and ongoing losses. Maximum rate and volume vary by clinical condition.
Geriatric useConsider reduced initial volume and slower infusion rate due to decreased cardiovascular reserve and higher risk of fluid overload. Monitor closely for signs of heart failure and electrolyte disturbances.

Use during pregnancy

1st trimesterAcetated Ringer's solution is generally considered safe in the first trimester when used for volume replacement or electrolyte balance under medical supervision. There is no known teratogenicity.
2nd trimesterSafe for use in the second trimester for fluid and electrolyte management. Monitor for fluid overload.
3rd trimesterSafe for use in the third trimester, but caution in patients with preeclampsia or impaired renal function due to risk of fluid overload.

Clinical note

Comprehensive clinical and safety monograph for ACETATED RINGER'S IN PLASTIC CONTAINER (ACETATED RINGER'S IN PLASTIC CONTAINER).

Placental transferElectrolytes and water freely cross the placenta. Acetate is rapidly metabolized and transferred to the fetus.
BreastfeedingAcetated Ringer's solution is compatible with breastfeeding. It contains electrolytes and water that are normal constituents of breast milk. No adverse effects are expected.
Lactation RatingL1 (Safe)
Teratogenic RiskNo fetal risks identified; acetated Ringer's solution is isotonic and used for fluid and electrolyte replenishment. No teratogenic effects reported in any trimester.
Fetal MonitoringMonitor maternal fluid balance, serum electrolytes, acid-base status, and urine output; fetal heart rate monitoring if indicated by maternal condition.
Fertility EffectsNo known effects on fertility; used as a physiological solution without reproductive toxicity.

Warnings & precautions

■ FDA Black Box Warning

Not available; no FDA boxed warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

HypernatremiaSevere metabolic alkalosisAnuria (in absence of dialysis)Severe renal impairment with oliguria

Clinical Precautions

PrecautionsMonitor serum electrolytes and acid-base status; avoid in patients with severe renal impairment or alkalosis; caution in heart failure, pulmonary edema, and conditions causing sodium retention.
Food/DietaryNo specific food interactions. However, dietary intake of sodium and potassium should be considered in patients with electrolyte imbalances or renal impairment.

Clinical Tips & Counseling

Clinical PearlsAcetated Ringer's is an isotonic crystalloid containing acetate as a bicarbonate precursor; it does not require hepatic metabolism for alkalinization, unlike lactate, making it preferable in patients with hepatic impairment or lactic acidosis. Monitor serum electrolytes and acid-base status during infusion, especially in renal impairment. Do not administer through same IV line with blood products due to risk of hemolysis from calcium content. Avoid use in metabolic alkalosis.
Patient AdviceThis solution is used to replace body fluids and electrolytes, often during surgery or dehydration. · Tell your doctor if you have kidney disease, heart failure, or are on a sodium-restricted diet. · You may experience swelling if too much fluid is given; report shortness of breath or leg swelling. · Notify your healthcare provider if you feel dizzy, have muscle cramps, or tingling sensations. · Do not suddenly stop treatment without consulting your doctor.

ACETATED RINGER'S IN PLASTIC CONTAINER Interactions

Loading safety data…

This overview is compiled from peer-reviewed clinical sources and FDA labeling. It's here to support — not replace — clinical judgment. Always verify dosing against your institution's current protocols before prescribing.

On this page

Mechanism of ActionDosing & administrationUse during pregnancyWarnings & precautionsDrug interactions

Compare with

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINERISOLYTE E IN PLASTIC CONTAINERISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINERISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINERISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

External sources

DailyMed (NIH) PubMed OpenFDA